Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Annual screening tests do not decrease deaths from prostate cancer

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington University School of Medicine in St. Louis.

6 Jan 2012

Investigational HSV vaccine shows promise against two genital herpes diseases

An investigational vaccine protected some women against infection from one of the two types of herpes simplex viruses that cause genital herpes, according to findings in the New England Journal of Medicine.

5 Jan 2012

Two new studies offer clearer picture of rise of hepatocellular carcinoma

Doctors have known for years that the incidence of deadly liver cancer is on the rise, but what is causing that trend has remained a mystery. Two recent Mayo Clinic studies published in the January issue of Mayo Clinic Proceedings offer a clearer picture of the rise of hepatocellular carcinoma (HCC), or liver cancer, which has tripled in the U.S. in the last three decades and has a 10 to 12 percent five-year survival rate when detected in later stages.

4 Jan 2012

Scientists show how HCV virus hijacks miR-122 in liver cells

Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.

2 Jan 2012

Detoxing this January useless but a long term effort may help: British Liver Trust

While many believe in detoxifying their systems after the season of indulgence, the British Liver Trust warns regarding January detoxes and urges people to think about their long-term health instead.

2 Jan 2012

CWRU receives NIDDK grant to study role of innate immunity in IBD

Investigators at Case Western Reserve University School of Medicine received a $6.75 million Program Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study the role of innate immunity in inflammatory bowel disease.

21 Dec 2011

NYC Council Member celebrates re-launch of Einstein's Gruss MRRC

At a morning ceremony today, New York City Council Member James Vacca, along with administrators and faculty members of Albert Einstein College of Medicine of Yeshiva University, celebrated the re-launch of Einstein's Gruss Magnetic Resonance Research Center.

17 Dec 2011

Isis announces addition of three new drug development candidates

Isis Pharmaceuticals, Inc. announced today that it has added three new drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.

15 Dec 2011

Liver transplantations for NASH-Cirrhosis increase dramatically

Nonalcoholic steatohepatitis (NASH) occurs when fat builds up in the liver. This accumulation of fat damages the liver and leads to cirrhosis. NASH is rapidly increasing in the U.S. mainly related to the epidemics of obesity and diabetes.

15 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced the initiation of two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, which are inhibitors of the hepatitis C NS5B polymerase.

12 Dec 2011

Enrollment complete in Boehringer Ingelheim's BI 201335 Phase III trial for HCV

Boehringer Ingelheim today announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus.

9 Dec 2011

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.

9 Dec 2011

Treating 'brain tsunamis' could stop many victims of major head injury from further damage

Treating 'brain tsunamis' or 'killer waves' could stop many victims of major head injury from suffering additional brain damage, a study published in Lancet Neurology has found.

8 Dec 2011

BCX4945 proves effective at clearing malaria infections

An antimalarial agent developed by researchers at Albert Einstein College of Medicine of Yeshiva University proved effective at clearing infections caused by the malaria parasite most lethal to humans - by literally starving the parasites to death. The novel research, carried out on a small number of non-human primates, could bolster efforts to develop more potent therapies against one of the world's leading killers.

8 Dec 2011

Fatty livers burn more fat, not less

When our livers become loaded with fat, it isn't because they are slacking. A new study of human patients in the December Cell Metabolism shows that fatty livers actually burn more fat, not less. All that "hard work" may be at the root of the organ damage that comes with nonalcoholic fatty liver disease (NAFLD), a condition associated with insulin resistance that affects about one in three in the U.S. population.

6 Dec 2011

Study evaluates whether genetic GST polymorphisms increase risk of ALD in alcoholics

It has been widely observed that only a small percentage of alcoholics develop cirrhosis of the liver, the most advanced form of alcoholic liver disease (ALD); the reason why all alcoholics do not develop such disease is not known. The present study from Spain, that includes original work and a meta-analysis, evaluates whether genetic polymorphisms that determine levels of glutathione-S-transferases (GST) relate to the risk of developing ALD among alcoholics.

6 Dec 2011

Albert Einstein College of Medicine and Montefiore establish Office of Clinical trials

Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University have established an Office of Clinical Trials (OCT) to bring new therapies more rapidly to patients through the facilitation of efficient, compliant and timely conduct and management of clinical studies.

6 Dec 2011

Endocrine Society supports policies that aim to combat pediatric obesity

Today, The Endocrine Society issued a Position Statement supporting policies that bring together doctors and other healthcare providers, family, schools and the community to combat pediatric obesity through education and encouragement of lifestyle modifications.

6 Dec 2011

Alcohol related liver problems on the rise among the young

According to the NHS figures there has been a huge increase in the number of young adults treated in hospital for serious liver problems brought on by drinking too much.

5 Dec 2011